Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493589 | 0.82 | HSD11B1 (0.57) | HSD11B1LMNAALDH1A1KMT2AFFAR1 | |
| SCHEMBL1493557 | 0.81 | HSD11B1 (0.48) | HSD11B1LMNAFFAR1HDAC6 | |
| SCHEMBL10673787 | 0.78 | HSD11B1 (0.50) | HSD11B1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL1493377 | 0.76 | HSD11B1 (0.74) | HSD11B1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL1493551 | 0.74 | HSD11B1 (0.48) | HSD11B1LMNAMEN1KMT2A | |
| SCHEMBL1493404 | 0.74 | HSD11B1 (0.64) | HSD11B1LMNAALDH1A1FFAR1HDAC6 | |
| SCHEMBL1612000 | 0.72 | HTT (0.45) | LMNAALDH1A1 | |
| SCHEMBL1493532 | 0.71 | HSD11B1 (0.54) | HSD11B1ALDH1A1MEN1KMT2AFFAR1 | |
| SCHEMBL10679587 | 0.71 | ALDH1A1 (0.52) | HSD11B1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL20514119 | 0.69 | APLNR (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HSD11B1 1201/4885LMNA 4145/4885RXRA 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.